Management of Ovarian Function in Premenopausal and Perimenopausal Patients With Early or Advanced Breast Cancer
What is the role of ovarian function suppression in the treatment of patients with early or advanced breast cancer before menopause? What factors should be clinically considered when deciding whether such a patient is a candidate or not for ovarian function suppression? Here is a new three-part video roundtable from JNCCN–Journal of the National Comprehensive Cancer Network in which breast cancer experts explore this topic, sharing their perspectives and professional experience to assist oncologists who face these questions daily in the clinic.
Join moderator Matthew P. Goetz, MD, and his distinguished colleagues Ann H. Partridge, MD, MPH, and Kathryn J. Ruddy, MD, MPH, as they walk viewers through the clinical considerations in therapeutic decision-making for several different patient scenarios—in the disease settings of both lower-risk and higher-risk invasive and noninvasive ductal carcinomas. The faculty members also review the SOFT and TEXT trial data as well as a recent EBCTCG meta-analysis of treatments for estrogen receptor–positive, early-stage breast cancer and discuss how to apply these findings. Furthermore, based on evidence from the POSITIVE trial, they addressed the implications of therapy interruption for patients who want to become pregnant during their treatment journey.
